A prognostic model, including quantitative fetal fibronectin, to predict preterm labour: the quids meta-analysis and prospective cohort study

Published date: September 2021

Additional Information: Funding Information: Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 25, No. 52. See the NIHR Journals Library website for further project information. The research reported in this issue of the journal was funded by the HTA programme as project number 14/32/01. The contractual start date was in December 2015. The draft report began editorial review in May 2019 and was accepted for publication in December 2019. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report. Declared competing interests of authors: Sarah J Stock reports grants from the National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme, non-financial support from Hologic, Inc. (Marlborough, MA, USA), non-financial support from Parsagen Diagnostics, Inc. (Boston, MA, USA) and non-financial support from Medix Biochemica Ab (Espoo, Finland) during the conduct of the study. In addition, Sarah J Stock declares membership of the HTA Programme Funding Committee (General) (2016 to present). Kathleen Boyd reports grants from the NIHR HTA programme and NIHR Public Health Research (PHR) programme outside the submitted work during the conduct of the study. Lorna Aucott declares membership of the PHR Research Funding Board (2017 to present). Rachel K Morris reports grants from the NIHR HTA and NIHR Research for Patient Benefit programmes outside the submitted work during the conduct of the study. Jon Dorling reports grants from the NIHR HTA programme and Nutrinia Ltd (Ramat Gan, Israel) outside the submitted work; the grant from Nutrinia Ltd (2017–18) was for part of his salary to work as an expert advisor on a trial. Jon Dorling was a member of the NIHR HTA General Board (2017–18) and the NIHR HTA Maternity, Newborn and Child Health Panel (2013–18). Manju Chandiramani reports that she undertakes unpaid advisory work for Hologic, Inc., unrelated to the submitted work, and has been supported by Hologic, Inc., to attend a conference in the preceding 12 months. Anna David reports personal fees from Hologic, Inc., outside the submitted work, and salary support from the NIHR UCLH/UCL Biomedical Research Centre. Asma Khalil reports grants and prediction tests from Parsagen Diagnostics, Inc., paid to the institution, during the conduct of the study and declares being a member of the HTA Programme Funding Committee (2018 to present). Andrew Shennan reports grants and prediction tests from Hologic, Inc., for basic science on preterm markers, paid to the institution, and was a member of the HTA Funding Committee (Commissioning) during the conduct of the study (2018 to present). Tina Lavender declares membership of the HTA Obesity Themed Call Board (2013). Ben Mol reports a Practitioner Fellowship from the National Health and Medical Research Council, personal fees from ObsEva SA (Geneva, Switzerland), personal fees and other funding from Merck Sharp & Dohme (Kenilworth, NJ, USA), personal fees from Guerbet (Villepinte, France), travel support to present at meetings from Guerbet, and grants from Merck Sharp & Dohme, outside the submitted work. Richard D Riley reports grants from the NIHR HTA programme outside the submitted work during the conduct of the study. Jane Norman reports grants from the NIHR HTA and the NIHR Global Health programmes and the Medical Research Council, and personal fees from Dilafor AB (Solna, Sweden), outside the submitted work, and was a member of the HTA Maternal, Neonatal and Child Health Panel during the conduct of the study (2013–18); she was a member of the NIHR HTA and Efficacy and Mechanism Evaluation (EME) Editorial Board (2012–14). John Norrie reports grants from the University of Aberdeen and the University of Edinburgh during the conduct of the study, and membership of the following NIHR boards: CPR Decision-Making Committee, HTA Programme Funding Committee (Commissioning), HTA Commissioning Sub-Board (Expression of Interest), HTA Funding Boards Policy Group, HTA Programme Funding Committee (General), HTA Post-board funding teleconference, Clinical Trials Unit Standing Advisory Committee, HTA and EME Editorial Board and Pre-exposure Prophylaxis Impact Review Panel during the conduct of the study.

Local EPrints ID: 485356

URI: http://eprints.soton.ac.uk/id/eprint/485356

DOI: doi:10.3310/HTA25520

ISSN: 1366-5278

PURE UUID: 36b1313f-8812-4ecc-870e-53e9c7b49ff6

ORCID for Jon Dorling: orcid.org/0000-0002-1691-3221

Date deposited: 05 Dec 2023 17:35

Last modified: 16 Apr 2024 02:08